In May, BCRC-WA welcomed the announcement that the Food and Drug Administration (the licencing body for new medications in the USA) had given approval for use of the drug Neratinib.
This is a drug used exclusively for patients with HER2-positive breast cancer. Neratinib, an oral drug, was evaluated in the ExteNET trial which commenced 8 years ago with the involvement of 497 cancer centres in 41 countries. We are proud to have been the world’s leading recruiter, and successfully passed an FDA audit in the lead-up to the drug’s approval.
Listen to Professor Arlene Chan & Shereen Jolly discuss Neratinib on Ten Eye Witness News.